Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Ovarian Cancer Drug Resistance Protein Identified

The American Cancer Society estimates that almost 14,000 women in the United States alone will die from ovarian cancer in 2019. Additionally, with cancer drug resistance rates on the rise, having a greater understanding of the underlying molecular mechanisms t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The American Cancer Society estimates that almost 14,000 women in the United States alone will die from ovarian cancer in 2019. Additionally, with cancer drug resistance rates on the rise, having a greater understanding of the underlying molecular mechanisms that lead to chemotherapy resistance is critical. Now, investigators at the George Washington University (GW) Cancer Center have identified that the extracellular regulated kinase (ERK) protein is an important mechanism behind platinum-resistance in platinum-resistant ovarian cancer.

Findings from the new study—published recently in Clinical Cancer Research through an article titled “ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer”—provide clinical evidence confirming a link between ERK and hypoxia-inducible factor (HIF-1α).

Platinum-based chemotherapy drugs are among the strongest and most widely used against cancer. Up to 80% of ovarian cancer patients develop platinum-resistance over the course of their treatment. Studies have found that HIF-1α—a subunit of HIF-1, a heterodimeric transcription factor that regulates multiple cellular pathways—is an important mechanism governing platinum resistance. However, the mechanism regulating HIF-1α stability in platinum-resistant ovarian cancer was largely unknown.

“Platinum-based chemotherapy is such a powerful treatment for cancer patients, however so many develop a resistance,” explained senior study investigator Wenge Zhu, PhD, associate professor of biochemistry and molecular medicine at the GW School of Medicine and Health Sciences. “We wanted to figure out how that resistance happens for the cancer cells.”

The research team evaluated a combination of inhibitors of HIF-1α, ERK, and TGF-β1 with platinum drugs by in vitro and in vivo experiments. They found prolyl hydroxylase domain-containing protein 2 (PHD2) to be an underlying layer of ERK. Zhu and his team observed that from clinical samples the activation of the ERK/PHD2/HIF-1α axis in platinum-resistant ovarian cancer patients, correlated highly with poor prognoses for patients.

“We first used a quantitative high-throughput combinational screen (qHTCS) to identify novel drugs that could resensitize PROC cells to cisplatin. Next, we evaluated the combination efficacy of inhibitors of HIF1α (YC-1), ERK (selumetinib), and TGFβ1 (SB431542) with platinum drugs by in vitro and in vivo experiments. Moreover, a novel TGFβ1/ERK/PHD2-mediated pathway regulating HIF1α stability in platinum-resistant ovarian cancer (PROC) was discovered.”

“We found that HIF-1α stabilization is regulated by the TGF-β1/ERK/PHD2 axis in platinum-resistant ovarian cancer cells,” Zhu said. “Now we can consider inhibiting any of those components as a potential strategy for treating platinum-resistant patients.”

This study also provides insight for further investigation into whether this novel mechanism regulates the development of tumors and future chemotherapy response.

“HIF1α stabilization is regulated by TGFβ1/ERK/PHD2 axis in PROC. Hence, inhibiting TGFβ1, ERK, or HIF1α is a potential strategy for treating patients with PROC,” the authors concluded.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides